Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 394 Cr.
- Current Price ₹ 266
- High / Low ₹ 377 / 246
- Stock P/E 43.1
- Book Value ₹ 45.4
- Dividend Yield 0.75 %
- ROCE 27.8 %
- ROE 23.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.9%
- Company has been maintaining a healthy dividend payout of 17.2%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
17.57 | 17.83 | 15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 79.95 | |
15.76 | 16.63 | 14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 64.26 | |
Operating Profit | 1.81 | 1.20 | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 15.69 |
OPM % | 10.30% | 6.73% | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 19.62% |
0.13 | 0.29 | 0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.16 | |
Interest | 0.51 | 0.43 | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 1.16 |
Depreciation | 0.43 | 0.44 | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.31 |
Profit before tax | 1.00 | 0.62 | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 13.38 |
Tax % | 32.00% | 29.03% | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | |
0.68 | 0.44 | 0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 9.15 | |
EPS in Rs | 1.42 | 0.81 | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 6.18 |
Dividend Payout % | 5.88% | 0.00% | 0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 25% |
3 Years: | 18% |
TTM: | -21% |
Compounded Profit Growth | |
---|---|
10 Years: | 41% |
5 Years: | 43% |
3 Years: | 11% |
TTM: | -43% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 56% |
3 Years: | 49% |
1 Year: | -29% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 30% |
3 Years: | 26% |
Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.60 | 1.80 | 1.80 | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 |
Reserves | 3.13 | 3.56 | 4.00 | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 52.42 |
4.66 | 3.75 | 3.46 | 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 23.83 | |
4.18 | 4.01 | 4.53 | 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 16.03 | 16.28 | |
Total Liabilities | 13.57 | 13.12 | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 96.87 | 107.34 |
6.03 | 6.12 | 6.94 | 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 34.61 | |
CWIP | 0.36 | 0.54 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.31 | 14.36 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 17.41 |
7.13 | 6.41 | 6.80 | 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 46.66 | 40.96 | |
Total Assets | 13.57 | 13.12 | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 96.87 | 107.34 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.68 | 0.73 | 1.18 | 1.52 | 0.83 | 1.41 | 3.50 | 8.05 | 10.90 | 9.62 | 9.14 | 14.82 | |
-0.81 | -0.90 | -0.66 | -0.72 | -0.97 | -1.45 | -4.17 | -5.18 | -7.62 | -8.16 | -2.64 | -20.29 | |
-0.70 | -0.08 | -0.64 | -0.29 | -0.07 | 1.94 | -0.07 | -1.23 | -3.56 | -0.76 | 2.76 | 0.96 | |
Net Cash Flow | 0.17 | -0.25 | -0.11 | 0.51 | -0.22 | 1.90 | -0.74 | 1.64 | -0.29 | 0.69 | 9.26 | -4.51 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 48.40 | 35.62 | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 |
Inventory Days | 100.95 | 107.00 | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 |
Days Payable | 82.49 | 80.05 | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 |
Cash Conversion Cycle | 66.86 | 62.57 | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 |
Working Capital Days | 52.77 | 44.01 | 60.79 | 34.82 | 56.87 | 56.55 | 57.68 | 49.20 | 52.48 | 70.77 | 68.54 | 79.83 |
ROCE % | 16.96% | 11.35% | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% |
Documents
Announcements
- Corporate Action-Board to consider Dividend 1d
- Board Meeting Intimation for Approval Of Audited Financial Results And Statements And Results For The 4Th Quarter And Year Ended 31St March 2024, Recommendation Of Final Dividend, If Any And Other Business /Agenda. 1d
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 2d
- Compliance Certificate - Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31/03/2024 15 Apr
- Certificate Under Regulation 40 (9) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March 2024 13 Apr
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries